Managing adverse events associated with BCMA-targeting agents in multiple myeloma: The role of the multidisciplinary team

Access to this content is not permitted for healthcare professionals based in the US.

Back to Education
Multiple Myeloma Watch Time: 38 mins

touchEXPERT OPINIONS Managing adverse events associated with BCMA-targeting agents in multiple myeloma: The role of the multidisciplinary team

Watch leading experts review adverse event management with BCMA-targeting multiple myeloma therapies, and consider the role of the multidisciplinary team.

Now Playing:
Up Next:
Miss Simona Degli Esposti
Moorfields Eye Hospital, London, UK
The role of the ophthalmologist: Managing adverse events in the treatment of multiple myeloma

Miss Degli Esposti outlines how the ocular toxicities that may occur with belantamab mafodotin treatment can be monitored for and managed. She also considers how eye care professionals can work with other members of the multidisciplinary team to ensure the best possible outcomes for patients.

1/3 Next Interview
Leave Feedback

In this interview, Miss Simona Degli Esposti answers the following questions:

  • What ocular toxicities have been observed with belantamab mafodotin?
  • How should a patient receiving belantamab mafodotin be monitored for possible ocular adverse events?
  • How is the severity of ocular events graded?
  • How can ocular events be managed in patients with multiple myeloma treated with belantamab mafodotin?
  • How can eye care professionals work with the wider patient care team to provide the best care possible?

Simona Degli Esposti is a consultant ophthalmologist at Moorfields Eye Hospital, London, UK.

Miss Degli Esposti completed medical school and ophthalmology training at the University of Bologna in Italy, where she graduated summa cum laude. She then completed a fellowship in medical retina and clinical trials at Moorfields Eye Hospital.

She has been working in the Clinical Research Facility at Moorfields Eye Hospital for several years, where she is involved in a number of clinical trials ranging from phase I to phase IV.

Miss Simona Degli Esposti discloses: Consulting fees and honoraria from GlaxoSmithKline. Speaker’s fees from Novartis.

Prof. Ibrahim Yakoub-Agha
Lille University Hospital, Lille, France
Managing adverse events associated with CAR T-cell therapy in the treatment of multiple myeloma

Prof. Yakoub-Agha reviews monitoring and management strategies for the possible adverse events associated with CAR T-cell therapy in the treatment of multiple myeloma. He also outlines key members of the multidisciplinary team who should be involved in the care of patients receiving CAR T-cell therapy.

2/3 Next Interview
Leave Feedback

In this interview, Prof. Ibrahim Yakoub-Agha answers the following questions:

  • What are the possible adverse events of BCMA-targeting CAR T-cell therapies?
  • How can adverse events be monitored in patients with multiple myeloma treated with CAR T-cell therapy, and where is MDT involvement important?
  • How can adverse events be managed should they arise?
  • How can haematologists work with the wider patient care team to provide the best care possible?

Ibrahim Yakoub-Agha is Professor of Hematology at Lille University and currently holds the position of Coordinating Professor for the Department of Hematology at Lille Faculty of Medicine. He has served as Head of the Hematopoietic Cell Transplantation and Cellular Therapy Unit at Lille University Hospital since 2008.

Prof. Yakoub-Agha is the current Chair of the Chronic Malignancies Working Party (CMWP) of the European Society for Blood and Marrow Transplantation (EBMT) and was President of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) from 2012 to 2016. read more

He is also Editor in Chief of Current Research in Translational Medicine; has authored more than 400 scientific articles in the field of allogeneic haematopoietic cell transplantation with a focus on studies concerning patients with myelodysplastic syndrome, multiple myeloma and immune effector cells such as CAR T cells; and has written several chapters for referential textbooks.

Prof. Ibrahim Yakoub-Agha discloses: Honoraria from Bristol Myers Squibb, Celgene, Gilead, Janssen, Kite and Novartis.

Dr Paula Rodríguez-Otero
University of Navarra, Pamplona, Spain
The role of MDT management for patients receiving BCMA-targeting agents in the treatment of multiple myeloma

Dr Rodríguez-Otero outlines how healthcare professionals can work together in a multidisciplinary team to monitor for and manage the possible adverse events associated with BCMA-targeted therapy in the treatment of multiple myeloma.

3/3 Leave Feedback
Leave Feedback

In this interview, Dr Paula Rodríguez-Otero answers the following questions:

  • In the context of BCMA-targeting agents, which aspects of patient care may benefit from an MDT approach?
  • Which healthcare professionals may need to be involved in the MDT for a patient treated with a BCMA-targeting agent, and why?
  • How can the MDT support a patient being treated with belantamab mafodotin?
  • How can an MDT support a patient being treated with BCMA-targeted CAR T-cell therapy?
  • What are key considerations to ensure the MDT works well together?

Paula Rodríguez-Otero studied medicine at the University of Navarra, Pamplona, Spain. She subsequently completed her residency training programme in haematology at the Clínica Universidad de Navarra and then became a member of the faculty.

After completing her PhD, she focused her clinical interests on the management and biology of allogeneic stem cell transplant, which brought her to undertake a clinical fellowship in the bone marrow transplant division at the Hôpital Saint-Louis, Paris, France. In 2011, she returned to the Department of Hematology at the University of Navarra, where she has since become a member of the Myeloma Unit and leads the clinical trials and immunotherapy programme under the direction of Prof. Jesús San-Miguel.

Dr Paula Rodríguez-Otero discloses: Consultancy/advisory boards for AbbVie, Celgene, GlaxoSmithKline, Janssen, Kite, Oncopeptides and Sanofi. Speakers bureau participation for Amgen, Celgene and Janssen.

Leave Feedback
Overview & Learning Objectives

In this activity, leading experts in multiple myeloma summarize management strategies for adverse events associated with the currently available BCMA-targeting therapies. They also consider how to work as part of a multidisciplinary team to provide each patient with the best possible care.

Learning Objectives

After watching this activity, participants should be better able to:

  • Use the most appropriate management strategy for patients experiencing ocular toxicity following treatment with a BCMA-targeting antibody-drug conjugate
  • Discuss the adverse events associated with BCMA-targeting CAR T-cell therapies, and how they can be managed
  • Recognize the importance of the multidisciplinary care team in the management of patients receiving a BCMA-targeting therapy for multiple myeloma

View and download resources from this activity to support your learning and share with colleagues.

Register to touchONCOLOGY for FREE
  • Peer-reviewed journals and expert opinions
  • Interactive CME and e-learning modules
  • Video conference highlights
Register For Free Now

This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
Feedback Close

Please provide feedback for this touchEXPERT OPINIONS on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

* = Mandatory Field

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72